Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event, suggested an observational trial weighted to emulate a clinical trial.

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among patients on dialysis. Cardiovascular risk was 36% higher with denosumab. Among adults ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on fractures but an increased risk for major adverse cardiovascular events (MACE ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

Patients on dialysis who take denosumab face a 36% higher risk for major cardiovascular adverse events than patients who take oral bisphosphonates, according to a study published Jan. 6 in Annals ...

a proposed denosumab biosimilar to Amgen’s PROLIA and XGEVA. GlyCoNex is a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies. The licensee ...

While patients taking the injectable denosumab (Prolia; Amgen) had 45% fewer fractures than those on bisphosphonates, their 3-year risk weighted risk ratio (RR) for MACE was 1.36 (95% CI 0.99-1.87), ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event ...